Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain

AIDS

Volumn 12, Issue 9, 1998, Pages 1015-1020

  Gómez Cano, María ^a   Rubio, Amalia ^b   Puig, Teresa ^c   Pérez Olmeda, Mayte ^a   Ruiz, Lidia ^c   Soriano, Vincent ^a,f   Pineda, Juan Antonio ^b   Zamora, Laura ^d   Xaus, Nuria ^e   Clotet, Bonaventura ^c   Leal, Manuel ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d BRISTOL MYERS SQUIBB   (United States)

^e Murex   (Spain)

^f NONE   (Spain)

Author keywords

Drug resistance; ERASE study; Multidrug resistance; Nucleoside analogues; Prevalence

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CODON; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; SPAIN;

EID: 7144242322     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199809000-00008     Document Type: Article

References (27)

1. Domingo E, Menéndez-Arias L, Quiñones-Mateu M, et al.: Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997, 48:99-128.
2. Ho D, Neumann A, Perelson A, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. Wei X, Ghosh S, Taylor M, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
4. Nájera I, Holguin A, Quiñones-Mateu M, et al.: Pol gene quasispecies of HIV: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
5. Erice A, Mayers D, Strike D, et al.: Primary infection with zidovudine-resistant HIV type 1. N Engl J Med 1993, 328:1163-1165.
6. Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ: Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors [letter]. AIDS 1997, 11:835-836.
7. Rubio A, Leal M, Pineda JA, et al.: Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naïve patients from 1989 to 1996 [letter]. AIDS 1997, 11:1184-1186.
8. De Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C: First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [letter]. AIDS 1996, 10:231-232.
9. García-Lerma G, Soriano V, Gómez-Cano M, et al.: Prevalence of zidovudine-resistant HIV-1 among rapid progressors [letter]. AIDS 1996, 10:1292-1293.
10. Imrie A, Carr A, Duncombe C, et al.: Primary infection with zidovudine-resistant HIV-1 does not adversely affect outcome at 1 year. J Infect Dis 1996, 174:195-198.
11. Boom R, Sol C, Salimans M, et al.: Rapid and simple method for purification of nucleid acids. J Clin Microbiol 1990, 28:495-503.
12. Stuyver L, Wyseur A, Rombout A, et al.: Line probe assay for rapid detection of drug selected mutations in the HIV-1 RT gene. Antimicrob Agents Chemother 1997, 41:284-291.
13. Schmit J, Cogniaux J, Hermans P, et al.: Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J Infect Dis 1996, 174:962-968.
14. Larder B, Darby G, Richman D: HIV with reduced sensitivity to zidovudine (ZDV) isolated during prolonged therapy. Science 1989, 243:1731-1734.
15. Wong J, Hezareh M, Gunthard H, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia. Science 1997, 278:1291-1295.
16. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
17. D'Aquila R, Johnson V, Welles, S, et al.: Zidovudine resistance and HIV type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
18. Leriche-Guerin K, Trabaud M, Cotte L, et al.: Correlation between antiretroviral resistance mutations. Biological parameters, and clinical evolution in zidovudine-treated patients infected with HIV type 1. Eur J Clin Microbiol Infect Dis 1997, 16:660-668.
19. Rubio A, Leal M, Rey C, Pineda JA, Sánchez-Quijano A, Lissen E: Short-term evolution of HIV-1 viremia and CD4+ cell counts in patients who have a primary mutation to zidovudine. AIDS 1998; 12:395-398.
20. Dietrich U, Ruppach S, Gehring S, et al.: Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors [letter]. AIDS 1997, 11:1532-1533.
21. Brun-Vézinet F, Boucher C, Loveday C, et al.: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997, 350:983-990.
22. Katzenstein D, Hammer S, Hughes M, ACTG 175 Virology Study Team: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4+ cells/μl. N Engl J Med 1996, 335:1091-1098.
23. Sharma P, Crumpacker D: Attenuated replication of HIV type 1 with didanosine-selected reverse transcriptase mutation. J Virol 1997, 71:8846-8851.
24. Back N, Berkhout B: Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of HIV type 1 reverse transcriptase. Antimicrobiol Agents Chemother 1997, 41:2484-2491.
25. CAESAR Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
26. Carpenter C, Fischl M, Hammer S, et al.: Antiretroviral therapy for HIV infection in 1997. JAMA 1997, 277:1962-1969.
27. Gómez-Cano V, Soriano V, Pérez-Olmeda M, et al.: Long-term suppression of HIV replication in patients having sustained benefit with zidovudine monotherapy: evidence for compartmentalization but not for eradication [letter]. AIDS 1998, 12:964-966.